A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous NonSmall Cell Lung Cancer That Is Stage IIIB With Pleural/Pericardial Effusion, Stage IV, or Recurrent
The purpose of this study is to determine if ruxolitinib, in combination with
Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of
nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.